The content of BioStock’s news and analysis is independent, but BioStock’s operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.
CEO Jeppe Øvlesen presents SynAct Pharma at Investing in Life Science 2026.
